Rocsur Dosage/Direction for Use

As with other neuromuscular blocking agents, the dosage of Rocuronium Bromide Injection should be individualized in each patient. The method of anesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose. The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery.
Inhalational anesthetics do potentiate the neuromuscular blocking effects of Rocuronium Bromide Injection. This potentiation however, becomes clinically relevant in the course of anesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with Rocuronium Bromide Injection should made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of Rocuronium Bromide Injection during long lasting procedures (longer than 1 hour) under inhalational anesthesia (see Interactions).
In adult patients, the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit.
Surgical Procedures: Tracheal intubation: The standard intubating dose during routine anesthesia is 0.6 mg rocuronium bromide per kg body weight, after which adequate intubation conditions are established within 60 seconds in nearly all patients. A dose of 1.0 mg rocuronium bromide per kg body weight is recommended for facilitating tracheal intubation conditions during rapid sequence induction of anesthesia, after which adequate intubation conditions are also established within 60 seconds in nearly all patients. If a dose of 0.6 mg rocuronium bromide per kg body weight is used for rapid sequence induction of anesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide. In patients undergoing Cesarean section it is recommended to only use a dose of 0.6 mg rocuronium bromide per kg body weight, since a 1.0 mg/kg dose has not been investigated in this patient group.
Maintenance dosing: The recommended maintenance dose is 0.15 mg rocuronium bromide per kg body weight; in the case of long-term inhalational anesthesia, this should be reduced to 0.075-0.1 mg rocuronium bromide per kg body weight. The maintenance doses should best be given when twitch height has recovered to 25% of control twitch height, or when 2 to 3 responses to train of four stimulations are present.
Continuous infusion: If Rocuronium Bromide Injection is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg rocuronium bromide per kg body weight and, when neuromuscular block starts to recover, to start administration by infusion. The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to train of four stimulations. In adults under intravenous anesthesia, the infusion rate required to maintain neuromuscular block at this level ranges from 0.3-0.6 mg.kg^-1.h^-1 and under inhalational rate ranges from 0.3-0.4 mg.kg^-1.h^-1. Continuous monitoring of neuromuscular block is recommended since infusion rate requirements vary from patient to patient and with the anesthetic method used.
Dosing in pediatric patients: For infants (28 days-23 months), children (2-11 years) and adolescents (12-18 years) the recommended intubation dose during routine anesthesia and maintenance dose are similar to those in adults.
For continuous infusion in pediatrics, the infusion rates, with exception of children, are the same as for adults. For children higher infusion rates might be necessary. For children the same initial infusion rates as for adults are recommended and this should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to train of four stimulation during the procedure.
There are insufficient data to support dose recommendations for the use of rocuronium bromide in neonates (0-1 month).
The experience with rocuronium bromide in rapid sequence induction in pediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitating tracheal intubation conditions during rapid sequence induction in pediatric patients.
Dosing in geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure: The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure during routine anesthesia is 0.6 mg rocuronium bromide per kg body weight. A dose of 0.6 mg per kg body weight should be considered for rapid sequence induction of anesthesia in patients in which a prolonged duration of action is expected. Regardless of the anesthetic technique used, the recommended maintenance dose for these patients is 0.075-0.1 mg rocuronium bromide per kg body weight, and the recommended infusion rate is 0.3-0.4 mg.kg^-1.h^-1 (see also previously mentioned Continuous infusion).
Dosing in overweight and obese patients: When used in overweight or obese patients with a body weight of 30% or more above ideal body weight) doses should be reduced taking into account a lean body mass.
Intensive Care Procedures: Tracheal intubation: For tracheal intubation, the same doses should be used as described previously under surgical procedures.
Maintenance Dosing: The use of an initial loading dose of 0.6 mg rocuronium bromide per kg body weight is recommended, followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1 to 2 twitches to train of four stimulations. Dosage should always be titrated to effect in the individual patient. The recommended initial infusion rate for the maintenance of a neuromuscular block of 80-90% (1 to 2 twitches to TOF stimulation) in adult patients is 0.3-0.6 mg.kg^-1.h^-1 during the first hour of administration, which will need to be decreased during the following 6-12 hours, according to the individual response. Thereafter, individual dose requirements remain relatively constant.
A large between patient variability in hourly infusion rates has been found in controlled clinical studies, with mean hourly infusion rates ranging from 0.2-0.5 mg.kg^-1.h^-1 depending on nature and extent of organ failure(s), concomitant medication and individual patient characteristics. To provide optimal individual patient control, monitoring of neuromuscular transmission is strongly recommended. Administration up to 7 days has been investigated. There are no data to support dose recommendations for the facilitation of mechanical ventilation in pediatric and geriatric patients.
Administration: Rocuronium Bromide Injection is administered intravenously either as a bolus injection or as a continuous infusion.